

June 29, 2021
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Onconova Therapeutics announces an update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer

TOKYO, Japan, June 29, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that its U.S. licensor for rigosertib, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova"), provided an update on June 28, 2021 (EST) on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC), commenting that the study supports the preclinical observation in melanoma of the up regulation of crucial cell surface molecules by rigosertib which may synergize with immune checkpoint blockade, as recently published in *Molecular Cancer*.

For Onconova's full press release, please visit Onconova's website:

<https://investor.onconova.com/press-releases>

About Rigosertib

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. SymBio obtained the development and commercialization licensing rights for Rigosertib from Onconova in July, 2011 for Japan and Korea.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS). Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. For more information, please visit <https://www.onconova.com>.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.